Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is strategically focused on innovative gene and cell therapies, particularly in the area of inherited retinal diseases, which positions the company to address significant unmet medical needs in this space. The potential upside for Ocugen’s stock is bolstered by the promising results of the OCU400 in current phase I/II clinical studies, which, if successful, could lead to strong efficacy and safety profiles. Additionally, attractive collaboration agreements and the potential for mergers and acquisitions further enhance the company's growth outlook and financial viability in the evolving biopharmaceutical market.

Bears say

Ocugen Inc. faces significant challenges, evidenced by its inability to secure necessary investments, which the company attributes to poor market conditions and limited time for Nasdaq compliance. Additionally, the company's pipeline, while promising, is at risk of becoming obsolete as advancements in treatment methods for retinal diseases may lead to increased competition. These factors collectively contribute to a negative outlook on Ocugen's stock, highlighting systemic issues that could hinder its financial stability and growth potential.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.